Published by Josh White on 1st July 2024
(Sharecast News) - Sareum Holdings announced positive topline results from its phase 1a clinical trial of SDC-1801, a dual TYK2/JAK1 kinase inhibitor under development for treating autoimmune diseases.
URL: http://www.digitallook.com/dl/news/story/34398172/...